TransEnterix announced last week that the FDA cleared their Senhance surgical robotics system for use in gynecologic and colorectal laparoscopic surgical procedures. The device has already received the CE mark.
Building on the known benefits of robotic surgery to reduce pain, scarring and recovery time after surgery, the Senhance’s differentiating features include haptic feedback and eye-sensing camera control. The Senhance also utilizes an open architecture, which allows hospitals to integrate the system into existing operating room equipment. TransEnterix also emphasizes the economic benefits of their system, which will compete with Intuitive’s da Vinci, by noting that the Senhance is operated with fully reusable instruments.
Also in development at TransEnterix is the SurgiBot System, a single-port robotic surgical platform. That system is not yet available in any market.